1-(4-methoxyphenyl)-3-(6-methyl-2-pyridinyl)thiourea is a chemical compound, often referred to as a **thiourea derivative**. These compounds are interesting for research due to their potential **biological activity** in various areas.
Here's a breakdown:
**Structure:**
* **Thiourea:** The core of this molecule is thiourea, which is a sulfur-containing analog of urea.
* **Substitutions:** The molecule has two specific substitutions:
* **4-methoxyphenyl:** A phenyl ring (benzene ring) with a methoxy (-OCH3) group attached at the 4th position.
* **6-methyl-2-pyridinyl:** A pyridine ring (nitrogen-containing aromatic ring) with a methyl (-CH3) group at the 6th position and the thiourea attached at the 2nd position.
**Potential Biological Activity:**
Thiourea derivatives often exhibit a wide range of biological activities, including:
* **Antimicrobial activity:** They can act against bacteria, fungi, and viruses.
* **Antioxidant activity:** They can protect cells from damage caused by free radicals.
* **Anti-inflammatory activity:** They can reduce inflammation.
* **Anticancer activity:** They can inhibit cancer cell growth.
* **Enzyme inhibition:** They can bind to and block the activity of specific enzymes.
**Research Importance:**
1-(4-methoxyphenyl)-3-(6-methyl-2-pyridinyl)thiourea, specifically, might be investigated for:
* **Drug development:** Its specific structure and potential activity could be optimized to create more potent and effective drugs.
* **Mechanistic studies:** Researchers could investigate how this compound interacts with biological targets, gaining insights into its mode of action.
* **Structure-activity relationship (SAR) studies:** By modifying the substituents, researchers could investigate how different parts of the molecule contribute to its activity, leading to the design of even more potent compounds.
**Important Note:**
It's crucial to understand that the actual importance of this specific compound in research is not readily available without further context or specific research publications. The information above provides a general overview of why thiourea derivatives are interesting for research.
ID Source | ID |
---|---|
PubMed CID | 2730951 |
CHEMBL ID | 1544141 |
CHEBI ID | 111193 |
Synonym |
---|
1-(4-methoxyphenyl)-3-(6-methyl-2-pyridyl)thiourea |
n-(4-methoxyphenyl)-n'-(6-methyl-2-pyridinyl)thiourea |
NCI60_034126 |
OPREA1_549411 |
smr000460397 |
n-(4-methoxyphenyl)-n'-(6-methyl-2-pyridyl)thiourea |
MLS000861613 |
nsc-695326 |
nsc695326 |
CHEBI:111193 |
AKOS001094336 |
1-(4-methoxyphenyl)-3-(6-methylpyridin-2-yl)thiourea |
HMS2778A22 |
CHEMBL1544141 |
1-(4-methoxyphenyl)-3-(6-methyl-2-pyridinyl)thiourea |
Q27190806 |
CCG-246701 |
Class | Description |
---|---|
thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 42.5615 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 3.5481 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 27.5110 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 11.2202 | 0.0058 | 6.0263 | 32.6427 | AID492947 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 23.1093 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 50.1187 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 2.4840 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 7.9433 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |